CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TheSlowLane who wrote (86)	2/10/1997 8:27:00 PM
From: Miljenko Zuanic	of 675

Paul, for me it is obviously that Mr. Rak was poorly informed (coincident or by purpose from Anaheim conference organizer) on current progress and trials for stroke treatment. He don't even know trade name for so-called TPA (Activase/Genentech), and he mentioned partially successful citicoline (FDA recommended to IPIC another P III trials), and failure of Lubeluzole. The booth article are actually promotion of TPA Activase, which up to date have limited success for well known reason, and it is not treat to Cerestat if it is successful in P III trials. Facts that Cerestat was presented in first day of conference is positive sign. Probably it is to early for even interim results!!? Neuroprotectants-neuroregenerators are actually post-stroke drugs, and they do not directly lower the stroke neurodemage or cease stroke progression. The Spanish research article, which I posted early ( R #79), unambiguously confirmed that the NMDA receptor antagonist (plasma glutamate levels) is a key point for early stroke treatment what Mr. Rak didn't know or mentioned in article . We should send him some article for general review. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next